Patent number: 12480952
Type: Grant
Filed: Apr 26, 2022
Date of Patent: Nov 25, 2025
Patent Publication Number: 20220252605
Assignee: CREATV MICROTECH, INC. (Potomac, MD)
The methods defined herein will allow oncologists to select better combinations and sequences of conventional cytotoxic and immunotherapies, as well as identify patients likely to show durable responses to immunotherapy.
___
This Patent is a very significant surprise. It covers what we've known about Leronlimab & LifeTracDx combo
6 months ago Dr. J said --- we do not yet know how much & how long to dose each of LL & ICI.
What did Cytodyn just add to our mCRC protocol --- LL dose amount & duration.
Naturally you THINK...the ICI mfgr's would / were, going to be point on LL & ICI's
Creatv just snagged monitoring & dosing the ICI's after LifeTracDx blood sampling
Patenting on "any ICI" !!
& 20/20 hindsight, that makes sense being ICI measuring / dosing too, are the follow-up steps of LifeTracDx detection.
But, i did NOT even think it was going to be a Creatv patent.
Thought was Creativ will "only" detect / measure/monitor cancer cells after LL causes upregulation.
Cytodyn & Creativ have now absolutely cornered the entirety of:
*Inducing Cold to Hold
*LL Dosing & Duration
*ICI Dosing & Duration
** Including "any ICI" as physician choosing **
@ only a 2026 $17.5m cost to Cytodyn
The significance of the upcoming initial mCRC data this month, is just.....I mean,,,,,,,,
Now, no pharma has ANY leverage on the combo below, due to Patents now granted:
LERONLIMAB / LIFETRACDX
WOW !!!
https://patents.justia.com/patent/12480952